Current Guidance* Previous Guidance Guidance $ Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic excluding COVID-19 % Increase Guidance $ Fiscal 2024 Revenue $4,012 - $4,027 (0.4%) to (0.1%) (0.5%) to (0.1%) 5.2% to 5.6% $4,000 - $4,050 GAAP EPS $3.37 - $3.44 84.2% to 88.0% $3.45 - $3.55 Non-GAAP EPS $4.04 - $4.11 2.0% to 3.8% $4.02 - $4.12 Q4 2024 Revenue $970 - $985 2.6% to 4.2% 2.9% to 4.5% 5.0% to 6.6% GAAP EPS $0.80 - $0.87 116.2% to 135.1% Non-GAAP EPS $0.97 - $1.04 9.0% to 16.9% *Fiscal 2024 has four fewer selling days compared to fiscal 2023. Factored into our guidance, we estimate the impact of the four fewer selling days to be a headwind of more than 100 bps for the full year. Fiscal 2024 and Q4 guidance incorporates Q3 performance, the addition of Endomagnetics, and impact from the temporary stop-ship of Horizon DXA systems (Skeletal) due to a non-conformance issue. Use of Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage

later in the release …

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.